- Approval Id
- 46d1131f5a24c426
- Drug Name
- GP CLARITHROMYCIN XR FILM-COATED TABLET 500MG
- Product Name
- GP CLARITHROMYCIN XR FILM-COATED TABLET 500MG
- Approval Number
- SIN16491P
- Approval Date
- 2022-05-13
- Registrant
- GOLDPLUS UNIVERSAL PTE LTD
- Licence Holder
- GOLDPLUS UNIVERSAL PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- PRESCRIPTION ONLY MEDICINES
- Dosage Form
- TABLET, FILM COATED, EXTENDED RELEASE
- Dosage
- <p><strong>DOSAGE & ADMINISTRATION:</strong><br>
<strong>Adults:</strong> The usual recommended dosage of Clarithromycin Extended-Release Tablets USP in adults is one 500 mg extended release tablet daily to be taken with food. In most severe infections, the dosage can be increased to two 500 mg extended release tablets daily. The usual duration of treatment is 7 to 14 days.</p>
<p><strong>Children older than 12 years:</strong> As for adults.</p>
<p><strong>Children younger than 12 years:</strong> The use of Clarithromycin Extended-Release Tablets USP has not been studied in children less than 12 years of age.</p>
<p>Clarithromycin Extended-Release Tablets USP should not be used in patients with renal impairment (creatinine clearance less than 30 mL/min). Clarithromycin immediate release tablets may be used in this patient population (see section Contraindication).</p>
<p>Do not crush or chew Clarithromycin Extended-Release Tablets USP.</p>
<p><u>Renal Impairment</u><br>
Clarithromycin extended release should not be used in patients with significant renal impairment (creatinine clearance less than 30 ml/min), as appropriate clarithromycin dosage reduction is not possible when administering this product. Clarithromycin immediate release tablets may be utilized in this patient population. Refer the dosing for immediate release formulation.</p>
- Route Of Administration
- ORAL
- Indication Info
- <p><strong>INDICATIONS & USAGE:</strong><br>
Clarithromycin Extended-Release Tablets USP is indicated for treatment of infections caused by susceptible organisms. Indications include:</p>
<p>Lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia (see section special warnings and clinical pharmacology regarding Sensitivity Testing – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>
<p>Upper respiratory tract infections for example, sinusitis and pharyngitis.</p>
<p>Clarithromycin Extended-Release Tablets USP is also indicated in skin and soft tissue infections of mild to moderate severity, for example folliculitis, cellulitis and erysipelas (see section special warnings and clinical pharmacology regarding Sensitivity Testing – <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p>
- Contraindications
- <p><strong>CONTRAINDICATION:</strong></p>
<ul>
<li>Hypersensitivity to macrolide antibiotic drugs or any of its excipients.</li>
<li>Concomitant administration of clarithromycin and any of the following drugs is contraindicated: astemizole, cisapride, pimozide, terfenadine as this may result in QT prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, and <em>torsades de pointes</em>.</li>
<li>Concomitant administration of clarithromycin and ergot alkaloids (e.g., ergotamine or dihydroergotamine) is contraindicated, as this may result in ergot toxicity.</li>
<li>Concomitant administration of clarithromycin and oral midazolam is contraindicated.</li>
<li>Clarithromycin should not be given to patients with history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including <em>torsades de pointes</em>.</li>
<li>Clarithromycin should not be given to patients with electrolyte disturbances (hypokalemia or hypomagnesaemia, due to the risk of prolongation of the QT-interval).</li>
<li>Clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment.</li>
<li>Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.</li>
<li>Clarithromycin (and other strong CYP3A4 inhibitors) should not be used concomitantly with colchicine.</li>
<li>As the dose cannot be reduced from 500 mg once-daily, clarithromycin modified release is contraindicated in patients with creatinine clearance less than 30 mL/min. Clarithromycin immediate release tablets may be utilized in this patient population.</li>
<li>Concomitant administration with ticagrelor or ranolazine is contraindicated.</li>
<li>Concomitant administration of clarithromycin and lomitapide is contraindicated</li>
</ul>
- Atc Code
- J01FA09
- Atc Item Name
- clarithromycin
- Pharma Manufacturer Name
- GOLDPLUS UNIVERSAL PTE LTD
